List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/592079/publications.pdf Version: 2024-02-01

		9254	5986
367	30,535	74	160
papers	citations	h-index	g-index
411	411	411	25480
all docs	docs citations	times ranked	citing authors

RIK WANDENBERCHE

#	Article	IF	CITATIONS
1	Classification of primary progressive aphasia and its variants. Neurology, 2011, 76, 1006-1014.	1.5	3,885
2	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
3	Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature, 2006, 442, 920-924.	13.7	1,386
4	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
5	Functional anatomy of a common semantic system for words and pictures. Nature, 1996, 383, 254-256.	13.7	1,151
6	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
7	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
8	¹⁸ Fâ€flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Annals of Neurology, 2010, 68, 319-329.	2.8	582
9	A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurology, The, 2012, 11, 54-65.	4.9	565
10	Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. New England Journal of Medicine, 2018, 378, 1691-1703.	13.9	512
11	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	3.8	501
12	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.4	423
13	Disrupted temporal lobe connections in semantic dementia. Brain, 1999, 122, 61-73.	3.7	403
14	The neural systems sustaining face and proper-name processing. Brain, 1998, 121, 2103-2118.	3.7	402
15	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
16	The Response of Left Temporal Cortex to Sentences. Journal of Cognitive Neuroscience, 2002, 14, 550-560.	1.1	330
17	Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Molecular Psychiatry, 2013, 18, 1225-1234.	4.1	321
18	Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. NeuroImage: Clinical, 2013, 2, 356-365.	1.4	297

#	Article	IF	CITATIONS
19	Phase 1 Study of the Pittsburgh Compound B Derivative ¹⁸ F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease. Journal of Nuclear Medicine, 2009, 50, 1251-1259.	2.8	273
20	Orienting Attention to Locations in Perceptual Versus Mental Representations. Journal of Cognitive Neuroscience, 2004, 16, 363-373.	1.1	264
21	The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1104-1119.	3.3	262
22	A Panâ€ <scp>E</scp> uropean Study of the <i>C9orf72</i> Repeat Associated with <scp>FTLD</scp> : Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	1.1	247
23	Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density. JAMA Neurology, 2015, 72, 287.	4.5	238
24	Functional Specificity of Superior Parietal Mediation of Spatial Shifting. NeuroImage, 2001, 14, 661-673.	2.1	213
25	Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimer's Research and Therapy, 2016, 8, 18.	3.0	208
26	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2016, 3, 623-636.	1.7	207
27	Whole-Body Biodistribution and Radiation Dosimetry of ¹⁸ F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging. Journal of Nuclear Medicine, 2009, 50, 818-822.	2.8	200
28	Genetic contribution of <i>FUS</i> to frontotemporal lobar degeneration. Neurology, 2010, 74, 366-371.	1.5	197
29	Serum biomarker for progranulinâ€associated frontotemporal lobar degeneration. Annals of Neurology, 2009, 65, 603-609.	2.8	195
30	Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Molecular Psychiatry, 2012, 17, 223-233.	4.1	179
31	The kinetic occipital region in human visual cortex. Cerebral Cortex, 1997, 7, 283-292.	1.6	178
32	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
33	Automated Quantification of ¹⁸ F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads. Journal of Nuclear Medicine, 2014, 55, 1623-1628.	2.8	174
34	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 104-114.	3.3	170
35	Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology, 2017, 88, 2302-2309.	1.5	169
36	Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2014, 35, 726.e11-726.e19.	1.5	158

#	Article	IF	CITATIONS
37	Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain, 2020, 143, 1632-1650.	3.7	158
38	Loss of <i>TBK1</i> is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology, 2015, 85, 2116-2125.	1.5	151
39	Remapping Attentional Priorities: Differential Contribution of Superior Parietal Lobule and Intraparietal Sulcus. Cerebral Cortex, 2007, 17, 2703-2712.	1.6	150
40	Alzheimer and Parkinson Diagnoses in Progranulin Null Mutation Carriers in an Extended Founder Family. Archives of Neurology, 2007, 64, 1436.	4.9	143
41	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
42	Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. Neurology, 2013, 81, 2103-2106.	1.5	139
43	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.4	134
44	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
45	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	2.8	132
46	CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. Human Molecular Genetics, 2008, 17, 313-322.	1.4	131
47	Attention to One or Two Features in Left or Right Visual Field: A Positron Emission Tomography Study. Journal of Neuroscience, 1997, 17, 3739-3750.	1.7	130
48	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	4.9	128
49	Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study. Lancet Neurology, The, 2015, 14, 814-822.	4.9	124
50	Lesion evidence for the critical role of the intraparietal sulcus in spatial attention. Brain, 2011, 134, 1694-1709.	3.7	122
51	A motion area in human visual cortex Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 993-997.	3.3	121
52	The influence of stimulus location on the brain activation pattern in detection and orientation discrimination: A PET study of visual attention. Brain, 1996, 119, 1263-1276.	3.7	117
53	Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. Human Mutation, 2007, 28, 416-416.	1.1	116
54	Similarity of fMRI Activity Patterns in Left Perirhinal Cortex Reflects Semantic Similarity between Words. Journal of Neuroscience, 2013, 33, 18597-18607.	1.7	115

#	Article	IF	CITATIONS
55	TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain, 2011, 134, 808-815.	3.7	110
56	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	0.9	106
57	Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy. Acta Neuropathologica, 2011, 121, 39-57.	3.9	105
58	Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 10-22.	1.8	102
59	Reproducibility of PET Activation Studies: Lessons from a Multi-Center European Experiment. NeuroImage, 1996, 4, 34-54.	2.1	99
60	Amyloid precursor protein mutation E682K at the alternative βâ€secretase cleavage βâ€2â€site increases Aβ generation. EMBO Molecular Medicine, 2011, 3, 291-302.	3.3	97
61	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
62	Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology, 2007, 68, 900-905.	1.5	96
63	A 22â€single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Al² ₄₂ . Alzheimer's and Dementia, 2015, 11, 1452-1460.	0.4	96
64	Spatial attention deficits in humans: The critical role of superior compared to inferior parietal lesions. Neuropsychologia, 2012, 50, 1092-1103.	0.7	95
65	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	3.9	93
66	Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with ¹⁸ F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles. Journal of Nuclear Medicine, 2019, 60, 107-114.	2.8	92
67	Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer's disease. Acta Neuropathologica, 2020, 139, 463-484.	3.9	91
68	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.4	90
69	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	3.7	89
70	A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. Brain, 2006, 129, 841-852.	3.7	88
71	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	1.1	87
72	Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Multiple Sclerosis Journal, 1997, 3, 8-17.	1.4	86

#	Article	IF	CITATIONS
73	Parcellation of parietal cortex: Convergence between lesion-symptom mapping and mapping of the intact functioning brain. Behavioural Brain Research, 2009, 199, 171-182.	1.2	86
74	Clinical features of <i>TBK1</i> carriers compared with <i>C9orf72</i> , <i>GRN</i> and non-mutation carriers in a Belgian cohort. Brain, 2016, 139, 452-467.	3.7	86
75	Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. NeuroImage: Clinical, 2013, 2, 497-511.	1.4	85
76	Distinct Clinical Characteristics of C9orf72 Expansion Carriers Compared With GRN, MAPT, and Nonmutation Carriers in a Flanders-Belgian FTLD Cohort. JAMA Neurology, 2013, 70, 365.	4.5	85
77	Clinical heterogeneity in 3 unrelated families linked to <i>VCP</i> p.Arg159His. Neurology, 2009, 73, 626-632.	1.5	84
78	Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Molecular Neurodegeneration, 2012, 7, 3.	4.4	77
79	Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein. Acta Neuropathologica, 2019, 138, 913-941.	3.9	75
80	Location- or Feature-Based Targeting of Peripheral Attention. NeuroImage, 2001, 14, 37-47.	2.1	74
81	DLB and PDD: a role for mutations in dementia and Parkinson disease genes?. Neurobiology of Aging, 2012, 33, 629.e5-629.e18.	1.5	73
82	Preclinical Evaluation of ¹⁸ F-JNJ64349311, a Novel PET Tracer for Tau Imaging. Journal of Nuclear Medicine, 2017, 58, 975-981.	2.8	72
83	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	1.8	70
84	Gesture Discrimination in Primary Progressive Aphasia: The Intersection between Gesture and Language Processing Pathways. Journal of Neuroscience, 2010, 30, 6334-6341.	1.7	68
85	An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer's disease. Acta Neuropathologica, 2018, 135, 827-837.	3.9	68
86	Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS. Neurobiology of Aging, 2009, 30, 1329-1331.	1.5	67
87	Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging. Psychiatry Research - Neuroimaging, 1996, 68, 11-22.	0.9	65
88	C9orf72 G4C2 repeat expansions in Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 2013, 34, 1712.e1-1712.e7.	1.5	65
89	Lesion neuroanatomy of the Sustained Attention to Response task. Neuropsychologia, 2009, 47, 2866-2875.	0.7	64
90	Microglial Upregulation of Progranulin as a Marker of Motor Neuron Degeneration. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1191-1200.	0.9	64

#	Article	IF	CITATIONS
91	Covert Shifts of Spatial Attention in the Macaque Monkey. Journal of Neuroscience, 2015, 35, 7695-7714.	1.7	64
92	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	3.0	64
93	Knowledge of visual attributes in the right hemisphere. Nature Neuroscience, 2006, 9, 964-970.	7.1	63
94	Word Reading and Posterior Temporal Dysfunction in Amnestic Mild Cognitive Impairment. Cerebral Cortex, 2006, 17, 542-551.	1.6	63
95	AÂ amyloid deposition in the language system and how the brain responds. Brain, 2007, 130, 2055-2069.	3.7	63
96	Blood Flow in Human Anterior Temporal Cortex Decreases with Stimulus Familiarity. NeuroImage, 1995, 2, 306-313.	2.1	62
97	Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Human Mutation, 2006, 27, 888-896.	1.1	62
98	Restoration of Progranulin Expression Rescues Cortical Neuron Generation in an Induced Pluripotent Stem Cell Model of Frontotemporal Dementia. Stem Cell Reports, 2015, 4, 16-24.	2.3	62
99	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research and Therapy, 2018, 10, 64.	3.0	62
100	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.4	62
101	Attentional responses to unattended stimuli in human parietal cortex. Brain, 2005, 128, 2843-2857.	3.7	61
102	Core auditory processing deficits in primary progressive aphasia. Brain, 2016, 139, 1817-1829.	3.7	60
103	Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients. Neurobiology of Aging, 2017, 51, 177.e9-177.e16.	1.5	60
104	No Association of Lower Hippocampal Volume With Alzheimer's Disease Pathology in Late-Life Depression. American Journal of Psychiatry, 2017, 174, 237-245.	4.0	59
105	APP Processing in Human Pluripotent Stem Cell-Derived Neurons Is Resistant to NSAID-Based Î ³ -Secretase Modulation. Stem Cell Reports, 2013, 1, 491-498.	2.3	58
106	Comparison of Different Generalizations of Clustering Coefficient and Local Efficiency for Weighted Undirected Graphs. Neural Computation, 2017, 29, 313-331.	1.3	58
107	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
108	Comparison of ELISA- and SIMOA-based quantification of plasma AÎ ² ratios for early detection of cerebral amyloidosis. Alzheimer's Research and Therapy, 2020, 12, 162.	3.0	58

#	Article	IF	CITATIONS
109	Distinct molecular patterns of TDP-43 pathology in Alzheimer's disease: relationship with clinical phenotypes. Acta Neuropathologica Communications, 2020, 8, 61.	2.4	58
110	Attentional priorities and access to short-term memory: Parietal interactions. Neurolmage, 2012, 62, 1551-1562.	2.1	57
111	Performance of [¹⁸ F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIAâ€AA recommendations for the neuropathologic diagnosis of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 25-34.	1.2	57
112	Convergence between Lesion-Symptom Mapping and Functional Magnetic Resonance Imaging of Spatially Selective Attention in the Intact Brain. Journal of Neuroscience, 2008, 28, 3359-3373.	1.7	56
113	Binary classification of 18F-flutemetamol PET using machine learning: Comparison with visual reads and structural MRI. NeuroImage, 2013, 64, 517-525.	2.1	56
114	Clinical Evidence of Disease Anticipation in Families Segregating a <i>C9orf72</i> Repeat Expansion. JAMA Neurology, 2017, 74, 445.	4.5	56
115	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 612-621.	0.9	55
116	Anterior temporal laterality in primary progressive aphasia shifts to the right. Annals of Neurology, 2005, 58, 362-370.	2.8	54
117	Combination of Biomarkers: PET [¹⁸ F]Flutemetamol Imaging and Structural MRI in Dementia and Mild Cognitive Impairment. Neurodegenerative Diseases, 2012, 10, 246-249.	0.8	52
118	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.5	52
119	Amyloid positron emission tomography with ¹⁸ Fâ€flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease. Alzheimer's and Dementia, 2013, 9, 295-301.	0.4	51
120	Classification of the primary progressive aphasias: principles and review of progress since 2011. Alzheimer's Research and Therapy, 2016, 8, 16.	3.0	49
121	Human brain activity related to speed discrimination tasks. Experimental Brain Research, 1998, 122, 9-22.	0.7	48
122	Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein E ε4 carriers. NeuroImage: Clinical, 2013, 2, 512-520.	1.4	47
123	Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 75.	3.0	47
124	Impaired recognition of body expressions in the behavioral variant of frontotemporal dementia. Neuropsychologia, 2015, 75, 496-504.	0.7	47
125	Metabolic patterns across core features in dementia with lewy bodies. Annals of Neurology, 2019, 85, 715-725.	2.8	47
126	Maintaining and Shifting Attention within Left or Right Hemifield. Cerebral Cortex, 2000, 10, 706-713.	1.6	46

#	Article	IF	CITATIONS
127	Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations. Molecular Neurodegeneration, 2015, 10, 30.	4.4	46
128	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.4	46
129	Characterization of Ubiquitinated Intraneuronal Inclusions in a Novel Belgian Frontotemporal Lobar Degeneration Family. Journal of Neuropathology and Experimental Neurology, 2006, 65, 289-301.	0.9	45
130	Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of <i>C9orf72</i> Repeat Expansion. JAMA Neurology, 2020, 77, 1008.	4.5	45
131	Autoimmune-mediated encephalitis. Neuroradiology, 2011, 53, 837-851.	1.1	44
132	Treatment results in primary intraspinal gliomas. Radiotherapy and Oncology, 1993, 29, 294-300.	0.3	43
133	Cross-modal representation of spoken and written word meaning in left pars triangularis. Neurolmage, 2017, 150, 292-307.	2.1	42
134	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. Movement Disorders, 2020, 35, 595-605.	2.2	42
135	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry, 2020, 10, 403.	2.4	42
136	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	2.8	42
137	Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 142-151.	3.3	41
138	A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 563-584.	3.3	41
139	The associative-semantic network for words and pictures: Effective connectivity and graph analysis. Brain and Language, 2013, 127, 264-272.	0.8	40
140	Functional dissociation between anterior temporal lobe and inferior frontal gyrus in the processing of dynamic body expressions: Insights from behavioral variant frontotemporal dementia. Human Brain Mapping, 2016, 37, 4472-4486.	1.9	39
141	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA Neurology, 2022, 79, 32.	4.5	38
142	Comparison of New Tau PET-Tracer Candidates With [¹⁸ F]T808 and [¹⁸ F]T807. Molecular Imaging, 2016, 15, 153601211562492.	0.7	37
143	Attention Shifts Recruit the Monkey Default Mode Network. Journal of Neuroscience, 2018, 38, 1202-1217.	1.7	37
144	Loss of DPP6 in neurodegenerative dementia: a genetic player in the dysfunction of neuronal excitability. Acta Neuropathologica, 2019, 137, 901-918.	3.9	37

#	Article	IF	CITATIONS
145	Aβ profiles generated by Alzheimer's disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Molecular Psychiatry, 2022, 27, 2821-2832.	4.1	37
146	Reversible posterior leucoencephalopathy during oral treatment with methotrexate. Journal of Neurology, 2004, 251, 226-228.	1.8	36
147	Explorative genetic study of UBQLN2 and PFN1 in an extended Flanders-Belgian cohort of frontotemporal lobar degeneration patients. Neurobiology of Aging, 2013, 34, 1711.e1-1711.e5.	1.5	36
148	Redefining the resolution of semantic knowledge in the brain: Advances made by the introduction of models of semantics in neuroimaging. Neuroscience and Biobehavioral Reviews, 2019, 103, 3-13.	2.9	36
149	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.4	36
150	Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation. Acta Neuropathologica, 2021, 141, 173-192.	3.9	35
151	Regions in the human brain activated by simultaneous orientation discrimination: a study with positron emission tomography. European Journal of Neuroscience, 1998, 10, 3689-3699.	1.2	34
152	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	1.5	34
153	Left perirhinal cortex codes for similarity in meaning between written words: Comparison with auditory word input. Neuropsychologia, 2015, 76, 4-16.	0.7	34
154	Amygdala atrophy affects emotion-related activity in face-responsive regions in frontotemporal degeneration. Cortex, 2016, 82, 179-191.	1.1	34
155	Follow-Up Study of Susceptibility Loci for Alzheimer's Disease and Onset Age Identified by Genome-Wide Association. Journal of Alzheimer's Disease, 2010, 19, 1169-1175.	1.2	33
156	The amodal system for conscious word and picture identification in the absence of a semantic task. NeuroImage, 2010, 49, 3295-3307.	2.1	33
157	Cytoarchitectonic mapping of attentional selection and reorienting in parietal cortex. NeuroImage, 2013, 67, 257-272.	2.1	33
158	Review of the Ethical Issues of a Biomarker-Based Diagnoses in the Early Stage of Alzheimer's Disease. Journal of Bioethical Inquiry, 2018, 15, 219-230.	0.9	33
159	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	2.1	33
160	Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts. Neurobiology of Aging, 2012, 33, 1004.e17-1004.e20.	1.5	32
161	NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients. Neurobiology of Aging, 2018, 61, 255.e1-255.e7.	1.5	32
162	Functional Similarity of Medial Superior Parietal Areas for Shift-Selective Attention Signals in Humans and Monkeys. Cerebral Cortex, 2017, 28, 1-15.	1.6	31

#	Article	IF	CITATIONS
163	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer's and Dementia, 2021, 17, 969-983.	0.4	31
164	Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. Brain, 2023, 146, 321-336.	3.7	30
165	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Molecular Neurodegeneration, 2022, 17, 27.	4.4	30
166	Cognitive aging and Alzheimer's disease. Postgraduate Medical Journal, 2005, 81, 343-352.	0.9	29
167	Phenotypic characteristics of Alzheimer patients carrying an <i>ABCA7</i> mutation. Neurology, 2016, 86, 2126-2133.	1.5	29
168	Functional Changes in the Language Network in Response to Increased Amyloid Î ² Deposition in Cognitively Intact Older Adults. Cerebral Cortex, 2016, 26, 358-373.	1.6	29
169	A Time-Varying Connectivity Analysis from Distributed EEG Sources: A Simulation Study. Brain Topography, 2018, 31, 721-737.	0.8	29
170	Serum neurofilament heavy chains as early marker of motor neuron degeneration. Annals of Clinical and Translational Neurology, 2019, 6, 1971-1979.	1.7	29
171	Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. Acta Neuropathologica Communications, 2019, 7, 178.	2.4	29
172	Combination of snapshot hyperspectral retinal imaging and optical coherence tomography to identify Alzheimer's disease patients. Alzheimer's Research and Therapy, 2020, 12, 144.	3.0	29
173	Characterizing the Clinical Features and Atrophy Patterns of <i>MAPT</i> -Related Frontotemporal Dementia With Disease Progression Modeling. Neurology, 2021, 97, e941-e952.	1.5	29
174	APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 65.	3.0	28
175	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	1.4	28
176	Cognitive Deficits during Status Epilepticus and Time Course of Recovery: A Case Report. Epilepsia, 2007, 48, 1979-1983.	2.6	27
177	3D Shape Perception in Posterior Cortical Atrophy: A Visual Neuroscience Perspective. Journal of Neuroscience, 2015, 35, 12673-12692.	1.7	27
178	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	1.5	27
179	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1119-1128. 	1.2	27
180	Corpus callosum macro and microstructure in late-life depression. Journal of Affective Disorders, 2017, 222, 63-70.	2.0	27

#	Article	IF	CITATIONS
181	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	1.4	27
182	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	3.7	27
183	Paradoxical features of word finding difficulty in primary progressive aphasia. Annals of Neurology, 2005, 57, 204-209.	2.8	26
184	The European Reference Network for Rare Neurological Diseases. Frontiers in Neurology, 2020, 11, 616569.	1.1	26
185	Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 84.	3.0	26
186	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	1.1	26
187	Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context. Alzheimer's Research and Therapy, 2017, 9, 92.	3.0	25
188	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 975-984.	0.9	25
189	Direct prospective comparison of 18F-FDG PET and arterial spin labelling MR using simultaneous PET/MR in patients referred for diagnosis of dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2142-2154.	3.3	25
190	Discovery of <i>N</i> -(4-[¹⁸ F]Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a New Promising Tau Positron Emission Tomography Imaging Tracer. Journal of Medicinal Chemistry, 2019, 62, 2974-2987.	2.9	24
191	Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults. Alzheimer's Research and Therapy, 2021, 13, 75.	3.0	24
192	BACE1 Levels Correlate with Phospho-Tau Levels in Human Cerebrospinal Fluid. Current Alzheimer Research, 2013, 10, 671-678.	0.7	24
193	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
194	Glucose metabolism in nine patients with probable sporadic Creutzfeldt–Jakob disease: FDG-PET study using SPM and individual patient analysis. Journal of Neurology, 2013, 260, 3055-3064.	1.8	23
195	Rare Variants in <i>PLD3</i> Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. Human Mutation, 2015, 36, 1226-1235.	1.1	23
196	Education modulates brain maintenance in presymptomatic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1124-1130.	0.9	23
197	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease. Acta Neuropathologica Communications, 2021, 9, 25.	2.4	23
198	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's and Dementia, 2021, 17, 1628-1640.	0.4	23

#	Article	IF	CITATIONS
199	Parametric imaging and quantitative analysis of the PET amyloid ligand [18 F]flutemetamol. NeuroImage, 2015, 121, 184-192.	2.1	22
200	Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT. Frontiers in Pharmacology, 2016, 7, 88.	1.6	22
201	Cholinergic depletion and basal forebrain volume in primary progressive aphasia. NeuroImage: Clinical, 2017, 13, 271-279.	1.4	22
202	Circadian sleep/wake-associated cells show dipeptide repeat protein aggregates in C9orf72-related ALS and FTLD cases. Acta Neuropathologica Communications, 2019, 7, 189.	2.4	22
203	Cognitive and Behavioral Manifestations in ALS: Beyond Motor System Involvement. Diagnostics, 2021, 11, 624.	1.3	22
204	Right Hemisphere Recruitment During Language Processing in Frontotemporal Lobar Degeneration and Alzheimer's Disease. Journal of Molecular Neuroscience, 2011, 45, 637-647.	1.1	21
205	Contribution of VPS35 genetic variability to LBD in the Flanders-Belgian population. Neurobiology of Aging, 2012, 33, 1844.e11-1844.e13.	1.5	21
206	Complement receptor 1 coding variant p.Ser1610Thr in Alzheimer's disease and related endophenotypes. Neurobiology of Aging, 2013, 34, 2235.e1-2235.e6.	1.5	21
207	Multivariate analysis reveals anatomical correlates of naming errors in primary progressive aphasia. Neurobiology of Aging, 2020, 88, 71-82.	1.5	21
208	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp> : A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	2.8	21
209	Moral processing deficit in behavioral variant frontotemporal dementia is associated with facial emotion recognition and brain changes in default mode and salience network areas. Brain and Behavior, 2017, 7, e00843.	1.0	20
210	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	1.5	20
211	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	1.7	20
212	Amnestic MCI Patients' Perspectives toward Disclosure of Amyloid PET Results in a Research Context. Neuroethics, 2017, 10, 281-297.	1.7	19
213	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Neurobiology of Aging, 2018, 66, 181.e3-181.e10.	1.5	19
214	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 997-1004.	0.9	19
215	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	2.8	19
216	TDP-43 interacts with pathological τ protein in Alzheimer's disease. Acta Neuropathologica, 2021, 141, 795-799.	3.9	19

#	Article	IF	CITATIONS
217	The interest of amyloid PET imaging in the diagnosis of Alzheimer's disease. Current Opinion in Neurology, 2013, 26, 646-655.	1.8	18
218	Left perirhinal cortex codes for semantic similarity between written words defined from cued word association. Neurolmage, 2019, 191, 127-139.	2.1	18
219	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	0.7	18
220	Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency. JAMA Network Open, 2021, 4, e2125584.	2.8	18
221	The spectrum of epilepsy caused by POLG mutations. Acta Neurologica Belgica, 2016, 116, 17-25.	0.5	17
222	Clinical variability and onset age modifiers in an extended Belgian GRN founder family. Neurobiology of Aging, 2018, 67, 84-94.	1.5	17
223	Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations. Alzheimer's Research and Therapy, 2020, 12, 108.	3.0	17
224	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiology of Aging, 2018, 62, 245.e1-245.e7.	1.5	16
225	Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia. Alzheimer's Research and Therapy, 2018, 10, 68.	3.0	16
226	Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. Frontiers in Aging Neuroscience, 2018, 10, 193.	1.7	16
227	Distinct [18F]THK5351 binding patterns in primary progressive aphasia variants. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2342-2357.	3.3	16
228	Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 946-958.	0.4	16
229	Symptomatic Internal Carotid Artery Dissecting Pseudoaneurysm: Endovascular Treatment by Stent-Graft. CardioVascular and Interventional Radiology, 2005, 28, 499-501.	0.9	15
230	Right fusiform response patterns reflect visual object identity rather than semantic similarity. NeuroImage, 2013, 83, 87-97.	2.1	15
231	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	1.5	15
232	Necrosomeâ€positive granulovacuolar degeneration is associated with TDPâ€43 pathological lesions in the hippocampus of ALS/FTLD cases. Neuropathology and Applied Neurobiology, 2021, 47, 328-345.	1.8	15
233	Pathogenesis and treatment of delayed post-traumatic syringomyelia. Acta Neurochirurgica, 1991, 110, 82-86.	0.9	14
234	Dissociations between spatial-attentional processes within parietal cortex: insights from hybrid spatial cueing and change detection paradigms. Frontiers in Human Neuroscience, 2013, 7, 366.	1.0	13

#	Article	IF	CITATIONS
235	The Relationship between Amyloid Deposition, Neurodegeneration, and Cognitive Decline in Dementia. Current Neurology and Neuroscience Reports, 2014, 14, 498.	2.0	13
236	Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains. Acta Neuropathologica Communications, 2015, 3, 68.	2.4	13
237	From information to followâ€up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 243-251.	1.8	13
238	Reproducibility of graph measures at the subject level using restingâ€state fMRI. Brain and Behavior, 2020, 10, 2336-2351.	1.0	13
239	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	1.2	13
240	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.4	13
241	Lower regional gray matter volume in the absence of higher cortical amyloid burden in late-life depression. Scientific Reports, 2021, 11, 15981.	1.6	13
242	Comparison of different Kalman filter approaches in deriving time varying connectivity from EEG data. , 2015, 2015, 2199-202.		12
243	An ALS case with 38 (G4C2)-repeats in the C9orf72 gene shows TDP-43 and sparse dipeptide repeat protein pathology. Acta Neuropathologica, 2019, 137, 855-858.	3.9	12
244	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in <i>C9orf72</i> expansion carriers in the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1325-1328.	0.9	12
245	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	3.0	12
246	Brain activity underlying stereotyped and non-stereotyped retrieval of learned stimulus-response associations. European Journal of Neuroscience, 1999, 11, 4037-4050.	1.2	11
247	In vivo amyloid imaging in cortical superficial siderosis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 469-471.	0.9	11
248	Face shape and face identity processing in behavioral variant fronto-temporal dementia: A specific deficit for familiarity and name recognition of famous faces. NeuroImage: Clinical, 2016, 11, 368-377.	1.4	11
249	Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1949-1960.	3.3	11
250	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	1.2	11
251	Phosphoâ€specific plasma pâ€ŧau181 assay detects clinical as well as asymptomatic Alzheimer's disease. Annals of Clinical and Translational Neurology, 2022, 9, 734-746.	1.7	11
252	Reproducibility and Robustness of Graph Measures of the Associative-Semantic Network. PLoS ONE, 2014, 9, e115215.	1.1	10

#	Article	IF	CITATIONS
253	Extended FTLD pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family. Alzheimer's Research and Therapy, 2018, 10, 7.	3.0	10
254	The medial temporal written word processing system. Cortex, 2019, 119, 287-300.	1.1	10
255	Stakeholders' Views on Early Diagnosis for Alzheimer's Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group Study. Journal of Bioethical Inquiry, 2019, 16, 45-59.	0.9	10
256	Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults. Journal of Neurochemistry, 2019, 149, 139-157.	2.1	10
257	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 608-616.	0.9	10
258	Premature termination codon mutations in ABCA7 contribute to Alzheimer's disease risk in Belgian patients. Neurobiology of Aging, 2021, 106, 307.e1-307.e7.	1.5	10
259	Spatial Stimulus Configuration and Attentional Selection: Extrastriate and Superior Parietal Interactions. Cerebral Cortex, 2013, 23, 2840-2854.	1.6	9
260	Noun and knowledge retrieval for biological and non-biological entities following right occipitotemporal lesions. Neuropsychologia, 2014, 62, 163-174.	0.7	9
261	Representation of Semantic Similarity in the Left Intraparietal Sulcus: Functional Magnetic Resonance Imaging Evidence. Frontiers in Human Neuroscience, 2017, 11, 402.	1.0	9
262	Toward a Universal Readout for ¹⁸ F-Labeled Amyloid Tracers: The CAPTAINs Study. Journal of Nuclear Medicine, 2021, 62, 999-1005.	2.8	9
263	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	1.7	9
264	Changes in the language system as amyloid- \hat{l}^2 accumulates. Brain, 2021, 144, 3756-3768.	3.7	9
265	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	4.4	9
266	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry, 2022, 27, 1990-1999.	4.1	9
267	Quantitative Analyses Help in Choosing Between Simultaneous vs. Separate EEG and fMRI. Frontiers in Neuroscience, 2018, 12, 1009.	1.4	8
268	Dipeptide repeat protein and TDP-43 pathology along the hypothalamic–pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases. Acta Neuropathologica, 2020, 140, 777-781.	3.9	8
269	Representation of associative and affective semantic similarity of abstract words in the lateral temporal perisylvian language regions. NeuroImage, 2020, 217, 116892.	2.1	8
270	The Role of Amyloid PET in Diagnosing Possible Transmissible Cerebral Amyloid Angiopathy in Young Adults with a History of Neurosurgery: A Case Series. Cerebrovascular Diseases, 2021, 50, 356-360.	0.8	8

#	Article	IF	CITATIONS
271	CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. Neurobiology of Aging, 2021, 103, 158.e1-158.e5.	1.5	8
272	Disease-related cortical thinning in presymptomatic granulin mutation carriers. Neurolmage: Clinical, 2021, 29, 102540.	1.4	8
273	Intracranial hypertension following intrathecal administration of liposomal cytarabine. Journal of Neurology, 2011, 258, 162-163.	1.8	7
274	Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo survey. Acta Neurologica Belgica, 2015, 115, 547-555.	0.5	7
275	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	1.2	7
276	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 158-168.	0.9	7
277	A Heteromodal Large-Scale Network for Spatial Attention. , 2005, , 29-34.		7
278	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	1.4	7
279	Dataâ€driven staging of genetic frontotemporal dementia using multiâ€modal <scp>MRI</scp> . Human Brain Mapping, 2022, 43, 1821-1835.	1.9	7
280	Neurosyphilis mimicking young-onset Alzheimer's disease: a case report explaining the pitfalls of FDG-PET. Acta Neurologica Belgica, 2016, 116, 207-210.	0.5	6
281	Electrocorticography of Spatial Shifting and Attentional Selection in Human Superior Parietal Cortex. Frontiers in Human Neuroscience, 2017, 11, 240.	1.0	6
282	An optimized MRI and PET based clinical protocol for improving the differential diagnosis of geriatric depression and Alzheimer's disease. Psychiatry Research - Neuroimaging, 2022, 320, 111443.	0.9	6
283	Monitoring the progression of Alzheimer's disease with τ-PET: Table 1. Brain, 2016, 139, 1318-1320.	3.7	5
284	Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays. SLAS Technology, 2018, 23, 188-197.	1.0	5
285	Contribution of homozygous and compound heterozygous missense mutations in VWA2 to Alzheimer's disease. Neurobiology of Aging, 2021, 99, 100.e17-100.e23.	1.5	5
286	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A Europeanâ€DLB consortium project. Alzheimer's and Dementia, 2021, 17, 1277-1286.	0.4	5
287	Orienting to different dimensions of word meaning alters the representation of word meaning in early processing regions. Cerebral Cortex, 2022, 32, 3302-3317.	1.6	5
288	Separation of β-amyloid binding and white matter uptake of (18)F-flutemetamol using spectral analysis. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 515-26.	1.0	5

#	Article	IF	CITATIONS
289	Frontotemporal Lobar Degeneration Case with an N-Terminal TUBA4A Mutation Exhibits Reduced TUBA4A Levels in the Brain and TDP-43 Pathology. Biomolecules, 2022, 12, 440.	1.8	5
290	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology, 2022, 99, .	1.5	5
291	Asymmetric Amyloid Deposition in the Brain Following Unilateral Electroconvulsive Therapy. Biological Psychiatry, 2017, 81, e11-e13.	0.7	4
292	Hierarchical spectral clustering of MRI for global-to-local shape analysis: Applied to brain variations in Alzheimer's disease. , 2017, , .		4
293	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	3.0	4
294	Effects of age, amyloid, sex, and <i>APOE</i> Îμ4 on the CSF proteome in normal cognition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12286.	1.2	4
295	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected nonâ€Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.4	4
296	Chronometry of word and picture identification: Common and modality-specific effects. NeuroImage, 2012, 59, 3701-3712.	2.1	3
297	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. Neurobiology of Aging, 2021, 108, 155-167.	1.5	3
298	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. Journal of Alzheimer's Disease, 2022, , 1-14.	1.2	3
299	Sense and sensitivity of novel criteria for frontotemporal dementia. Brain, 2011, 134, 2450-2453.	3.7	2
300	[P4â€"189]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1337.	0.4	2
301	Amnestic MCI Patients' Perspectives on Volunteer Participation in a Research Context. Journal of Clinical Research & Bioethics, 2017, 08, .	0.2	2
302	A familyâ€based genetic study identifies mutations in TLR9 impairing receptor activation: A role for innate immunity in AD pathogenesis. Alzheimer's and Dementia, 2020, 16, e047212.	0.4	2
303	No association of CpG SNP rs9357140 with onset age in Belgian C9orf72 repeat expansion carriers. Neurobiology of Aging, 2021, 97, 145.e1-145.e4.	1.5	2
304	Family-based exome sequencing identifies RBM45 as a possible candidate gene for frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiology of Disease, 2021, 156, 105421.	2.1	2
305	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	1.1	2
306	Left Frontal White Matter Links to Rhythm Processing Relevant to Speech Production in Apraxia of Speech. Neurobiology of Language (Cambridge, Mass), 2022, 3, 515-537.	1.7	2

#	Article	IF	CITATIONS
307	Differences in personality between a medical and a surgical practioner, and between a medical neurologist and a surgical one. Acta Neurochirurgica, 1995, 132, 215-216.	0.9	1
308	Reversible posterior leukoencephalopathy syndrome. Translational Neuroscience, 2010, 1, .	0.7	1
309	[P2–212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER's DISEASE (EMIFâ€AD): THE BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2017, 13, P691.	0.4	1
310	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. Alzheimer's and Dementia, 2020, 16, e036954.	0.4	1
311	Left frontal white matter atrophy links to timing mechanisms relevant for apraxia of speech. Alzheimer's and Dementia, 2020, 16, e044713.	0.4	1
312	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 336-339.	0.9	1
313	Lack of association between bridging integrator 1 (<i>BIN1</i>) rs744373 polymorphism and tauâ€PET load in cognitively intact older adults. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12227.	1.8	1
314	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	1.5	1
315	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. Journal of Neurology, 2022, 269, 4322-4332.	1.8	1
316	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	1.7	1
317	Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, .	0.4	1
318	Classification of 18F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth. European Journal of Nuclear Medicine and Molecular Imaging, 2022, , 1.	3.3	1
319	Invasion of a subcutaneous <i>Aspergillus</i> abscess into the brain. European Journal of Neurology, 1995, 2, 219-222.	1.7	0
320	Astronomia nova to human brain mapping. Neural Networks, 2006, 19, 1453-1454.	3.3	0
321	Subject classification from [18F]flutemetamol data into categories of raised or low levels of beta-amyloid: Concordance between quantitative and visual assessment. NeuroImage, 2010, 52, S144.	2.1	0
322	O1-03-01: In-depth molecular genetic analysis of CLU in Alzheimer's disease. , 2010, 6, S73-S74.		0
323	O3-04-01: Impairments of 3D visual perception in posterior cortical atrophy: Psychophysical, structural and functional anatomical basis. , 2013, 9, P524-P524.		0
324	O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test. , 2015, 11, P272-P272.		0

#	Article	IF	CITATIONS
325	P3-147: Brain amyloidosis is associated with worse cognitive performance in both the cognitively normal and impaired stages: A [18 F]flutemetamol PET study. , 2015, 11, P682-P683.		0
326	IC-P-019: Brain amyloidosis is associated with worse cognitive performance in both the cognitively normal and impaired stages: A [18 F]flutemetamol PET study. , 2015, 11, P23-P24.		0
327	P3-017: Rare variants in PLD3 do not increase risk in a belgian cohort of early-onset Alzheimer dementia patients. , 2015, 11, P626-P626.		0
328	O2-10-03: In vivo characterization of basal forebrain atrophy and cholinergic denervation in primary progressive aphasia. , 2015, 11, P198-P198.		0
329	P4-194: The identification of high-penetrant loss-of-function mutations in abca7 in Alzheimer's disease. , 2015, 11, P854-P854.		0
330	DT-02-01: Loss-of-function mutations in TBK1 are frequently associated with frontotemporal lobar degeneration in a belgian patient cohort. , 2015, 11, P333-P333.		0
331	P1-350: 3D-Shape Perception in Amnestic Mild Cognitive Impairment. , 2016, 12, P563-P564.		0
332	P4â€122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1059.	0.4	0
333	P1-319: The Effect of Gray Matter Volume and Amyloid Load on Normal Cognitive Performance in Cognitively Intact Older Adults. , 2016, 12, P547-P547.		0
334	P4â€126: Evaluation of a Novel Array of SNP (Single Nucleotide Polymorphism) Markers in Amyloidâ€PET Stratified Samples from MCI and Cognitively Normal Individuals. Alzheimer's and Dementia, 2016, 12, P1061.	0.4	0
335	Knowing your enemy: from post-mortem scene reconstruction to real-time monitoring of the spread of tau and amyloid. Brain, 2017, 140, 1179-1182.	3.7	0
336	[P3–385]: VISUAL READING OF AMYLOIDâ€₽ET IN MCI CHALLENGED: SHOULD WE CONSIDER ALTERNATIVE METHODS?. Alzheimer's and Dementia, 2017, 13, P1107.	0.4	0
337	[P1–134]: ENRICHMENT OF AMYLOIDâ€POSITIVE SAMPLES BY PET FROM EARLY SYMPTOMATIC AND PRODROMAL COHORT. Alzheimer's and Dementia, 2017, 13, P293.	0.4	0
338	[P1–289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF Aβ OR AMYLOIDâ€PET) IN THE EMIFâ€AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2017, 13, P361.	0.4	0
339	[P2–116]: TRANSCRIPTOME ANALYSIS IN BLOOD AND BRAIN IDENTIFIES GENE EXPRESSION REGULATION AND CORRESPONDING QUANTITATIVE TRAIT LOCI IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P651.	0.4	0
340	P3â€128: EXPLORING THE MOLECULAR MECHANISM OF NEURONAL HYPEREXCITABILITY IN DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1116.	0.4	0
341	O3â€10â€03: A POLYGENIC AD RISK SCORE PREDICTS AMYLOID ACCUMULATION OVER A 6â€YEAR INTERVAL IN COGNITIVELY INTACT OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1041.	0.4	0
342	ICâ€Pâ€068: A POLYGENIC AD RISK SCORE PREDICTS AMYLOID ACCUMULATION OVER A 6â€YEAR INTERVAL IN COGNITIVELY INTACT OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P61.	0.4	0

#	Article	IF	CITATIONS
343	Recessive missense variants in VWA2 increase risk of developing Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e039791.	0.4	0
344	ABCA7 PTC mutation carriers present with Alzheimer's disease pathology and cerebral amyloid angiopathy. Alzheimer's and Dementia, 2020, 16, e041513.	0.4	0
345	Differential involvement of limbic and paralimbic cortex in episodic memory processing in cognitive aging and neurodegeneration. Alzheimer's and Dementia, 2020, 16, e044516.	0.4	0
346	Longitudinal changes in [18 F]Flutemetamol load in cognitively intact APOE ε4 carriers vs noncarriers: Comparison of three reference regions. Alzheimer's and Dementia, 2020, 16, e044534.	0.4	0
347	Classification of 18 Fâ€flutemetamol scans using machine learning with neuropathology as standard of truth. Alzheimer's and Dementia, 2020, 16, e044550.	0.4	0
348	Comparison of two analytical platforms for bloodâ€based surrogate biomarkers of amyloid pathology. Alzheimer's and Dementia, 2020, 16, e045110.	0.4	0
349	Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. Alzheimer's and Dementia, 2020, 16, e046102.	0.4	0
350	Hierarchical involvement of molecular players in human neocortex in the course of preclinical and symptomatic Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e047351.	0.4	0
351	Posterior Intraparietal Sulcus Mediates Detection of Salient Stimuli Outside the Endogenous Focus of Attention. Cerebral Cortex, 2021, , .	1.6	0
352	Location- or Feature-based Targeting of Spatial Attention. , 2005, , 407-411.		0
353	Comparison of kinetic modelling strategies of N-[11C]-methylpiperidin-4-yl-proprionate ([11C]-PMP) in normals and patients with mild cognitive impairment (MCI). Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S593-S593.	2.4	0
354	Processing of Pitch, Rhythm and Timbre in Primary Progressive Aphasia. Frontiers in Human Neuroscience, 0, 6, .	1.0	0
355	3D shape perception in strabismus subjects. Acta Ophthalmologica, 2014, 92, 0-0.	0.6	0
356	Longitudinal changes in the brain language system as amyloid accumulates. Alzheimer's and Dementia, 2021, 17, .	0.4	0
357	Pattern of progression in MAPTâ€related frontotemporal dementia: Results from the GENFI study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
358	Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
359	Detecting clinical progression from abnormal regional brain volumes at baseline in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
360	A dataâ€driven disease progression model of fluid biomarkers in genetic FTD. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	CITATIONS
361	Intervalâ€specific likelihood ratios for improving differential diagnosis of Alzheimer's disease using biomarkers in cerebrospinal fluid. Alzheimer's and Dementia, 2021, 17, .	0.4	0
362	Current status and quantitative results of the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
363	From brain volumes to subgroup classification in genetic mutation carriers for frontotemporal dementia: A cluster analysis in the GENFI study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
364	Rare missense mutations and compound heterozygous mutations in <i>ABCA7</i> contribute to Alzheimer's disease in Belgian patients. Alzheimer's and Dementia, 2021, 17, e051341.	0.4	0
365	A case of vitamin B12 deficiency neurological syndrome in a young adult due to late-onset cobalamin C (CblC) deficiency: a diagnostic challenge. Biochemia Medica, 2022, 32, 020802.	1.2	0
366	Assessment of Alzheimer's disease polygenic risk score on longitudinal amyloid accumulation in cognitively intact older adults Alzheimer's and Dementia, 2021, 17 Suppl 3, e055201.	0.4	0
367	Genotype-phenotype of PSEN1 p.CYS263PHE carriers in Flanders-Belgian Alzheimer's disease patients Alzheimer's and Dementia, 2021, 17 Suppl 3, e055244.	0.4	Ο